|
|
 |
|
Total Number of Holdings (excluding cash): 50
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
306,942 |
$86,987,362.80 |
7.81% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
68,040 |
$85,159,544.40 |
7.65% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,765,507 |
$81,416,526.08 |
7.31% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
532,662 |
$77,337,195.78 |
6.95% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
296,064 |
$74,987,089.92 |
6.74% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,383,600 |
$43,429,192.00 |
3.90% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
181,644 |
$42,749,915.40 |
3.84% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
268,910 |
$42,318,366.70 |
3.80% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
510,414 |
$40,026,665.88 |
3.60% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
91,538 |
$39,730,238.14 |
3.57% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
49,252 |
$39,221,337.68 |
3.52% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
68,450 |
$37,066,359.50 |
3.33% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
72,269 |
$36,766,853.75 |
3.30% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
315,814 |
$35,772,251.78 |
3.21% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
589,027 |
$35,677,365.39 |
3.20% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
438,375 |
$27,543,101.25 |
2.47% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
125,117 |
$26,827,587.14 |
2.41% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
90,887 |
$24,351,353.91 |
2.19% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
157,999 |
$19,198,458.49 |
1.72% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
27,112 |
$17,042,603.20 |
1.53% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
564,503 |
$13,288,400.62 |
1.19% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
56,367 |
$13,191,569.01 |
1.18% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
230,460 |
$12,917,283.00 |
1.16% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
92,982 |
$12,733,884.90 |
1.14% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
38,076 |
$11,660,394.24 |
1.05% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
669,538 |
$9,855,599.36 |
0.89% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
38,971 |
$9,216,641.50 |
0.83% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
214,596 |
$6,815,568.96 |
0.61% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
87,592 |
$6,340,784.88 |
0.57% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
313,121 |
$6,027,579.25 |
0.54% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
19,250 |
$5,746,125.00 |
0.52% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
34,402 |
$5,706,603.76 |
0.51% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
100,744 |
$5,641,664.00 |
0.51% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
39,351 |
$5,685,825.99 |
0.51% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
219,499 |
$5,614,784.42 |
0.50% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
48,260 |
$5,471,236.20 |
0.49% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
239,496 |
$5,436,559.20 |
0.49% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
157,906 |
$5,375,120.24 |
0.48% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,227 |
$5,024,910.00 |
0.45% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
46,045 |
$4,979,306.30 |
0.45% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
37,027 |
$5,056,036.85 |
0.45% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
61,230 |
$4,904,523.00 |
0.44% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
116,406 |
$4,667,880.60 |
0.42% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
59,056 |
$4,362,466.72 |
0.39% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
82,523 |
$4,356,389.17 |
0.39% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
66,392 |
$3,883,932.00 |
0.35% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
51,804 |
$3,860,952.12 |
0.35% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
189,205 |
$3,729,230.55 |
0.33% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
94,491 |
$3,716,331.03 |
0.33% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
80,240 |
$2,790,747.20 |
0.25% |
| US Dollar |
$USD |
|
Other |
1,552,705 |
$1,552,704.50 |
0.14% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|